Circulating microRNA-133a in Patients With Arterial Hypertension, Hypertensive Heart Disease, and Left Ventricular Diastolic Dysfunction

Aim: The aim of the work was to study the circulating microRNA-133a levels in blood plasma of patients with arterial hypertension (AH), hypertensive heart disease (HHD), and left ventricular (LV) diastolic dysfunction (DD).Materials and Methods: A total of 48 patients with grade 2–3 AH and HHD at th...

Full description

Bibliographic Details
Main Authors: Sergiy M. Koval, Iryna O. Snihurska, Kostiantyn O. Yushko, Olga V. Mysnychenko, Marina Yu. Penkova, Olga M. Lytvynova, Alexander E. Berezin, Vadym S. Lytvynov
Format: Article
Language:English
Published: Frontiers Media S.A. 2020-07-01
Series:Frontiers in Cardiovascular Medicine
Subjects:
Online Access:https://www.frontiersin.org/article/10.3389/fcvm.2020.00104/full
id doaj-256c2dfcaed34228be75ded0664750f6
record_format Article
spelling doaj-256c2dfcaed34228be75ded0664750f62020-11-25T03:12:40ZengFrontiers Media S.A.Frontiers in Cardiovascular Medicine2297-055X2020-07-01710.3389/fcvm.2020.00104532843Circulating microRNA-133a in Patients With Arterial Hypertension, Hypertensive Heart Disease, and Left Ventricular Diastolic DysfunctionSergiy M. Koval0Iryna O. Snihurska1Kostiantyn O. Yushko2Olga V. Mysnychenko3Marina Yu. Penkova4Olga M. Lytvynova5Alexander E. Berezin6Vadym S. Lytvynov7Department of Arterial Hypertension and Prevention of Its Complications, Government Institution “L.T. Malaya Therapy National Institute of the National Academy of Medical Science of Ukraine, ” Kharkiv, UkraineDepartment of Arterial Hypertension and Prevention of Its Complications, Government Institution “L.T. Malaya Therapy National Institute of the National Academy of Medical Science of Ukraine, ” Kharkiv, UkraineDepartment of Arterial Hypertension and Prevention of Its Complications, Government Institution “L.T. Malaya Therapy National Institute of the National Academy of Medical Science of Ukraine, ” Kharkiv, UkraineDepartment of Arterial Hypertension and Prevention of Its Complications, Government Institution “L.T. Malaya Therapy National Institute of the National Academy of Medical Science of Ukraine, ” Kharkiv, UkraineDepartment of Arterial Hypertension and Prevention of Its Complications, Government Institution “L.T. Malaya Therapy National Institute of the National Academy of Medical Science of Ukraine, ” Kharkiv, UkraineDepartment of Laboratory Diagnostics, National University of Pharmacy, Kharkiv, UkraineInternal Medicine Department, Zaporizhia State Medical University, Zaporizhzhia, UkraineDepartment of Therapy, Rheumatology and Clinical Pharmacology, Kharkiv Medical Academy of Postgraduate Education (KhMAPE), Kharkiv, UkraineAim: The aim of the work was to study the circulating microRNA-133a levels in blood plasma of patients with arterial hypertension (AH), hypertensive heart disease (HHD), and left ventricular (LV) diastolic dysfunction (DD).Materials and Methods: A total of 48 patients with grade 2–3 AH and HHD at the age of 52.23 ± 7.26 (23 patients had LV DD [main group] and 25 patients had normal LV diastolic function [comparison group]) and 21 practically healthy individuals of comparable gender and age were examined. Diagnosis of AH and HHD was carried out according to the 2018 ESC/ESH recommendations. LV DD was determined according to the 2016 ASE/EACVI recommendations. Plasma microRNA-133a level was obtained by polymerase chain reaction using the CFX96 Touch System (BioRad), ≪TaqMan microRNA Assay≫ and ≪TaqMan® Universal PCR Master Mix≫ reagent kits (Thermo Fisher Scientific, USA).Results: We have found that in patients from the main and comparison groups plasma microRNA-133a levels were significantly lower than in practically healthy individuals (0.094 [0.067, 0.147]) and (0.182 [0.102, 0.301]) vs. (0.382 [0.198,0.474]), p = 0.002 and p = 0.04, respectively. In all this among patients with AH, HHD, and LV DD, plasma microRNA-133a levels were significantly lower than in patients with AH, HHD, and normal diastolic function (p = 0.03). In the main and comparison groups there was a statistically significant negative relationship between plasma microRNA-133a level and left ventricular mass index (LVMI) (R = −0.40, p = 0.003 and R = −0.35, p = 0.04, respectively).Conclusions: The findings suggest the significant role of decreased microRNA-133a levels in blood plasma of patients with AH in the pathogenesis and development of both HHD and LV DD.https://www.frontiersin.org/article/10.3389/fcvm.2020.00104/fullarterial hypertensionhypertensive heart diseasemicroRNA-133aleft ventricular diastolic dysfunctionepigenetics
collection DOAJ
language English
format Article
sources DOAJ
author Sergiy M. Koval
Iryna O. Snihurska
Kostiantyn O. Yushko
Olga V. Mysnychenko
Marina Yu. Penkova
Olga M. Lytvynova
Alexander E. Berezin
Vadym S. Lytvynov
spellingShingle Sergiy M. Koval
Iryna O. Snihurska
Kostiantyn O. Yushko
Olga V. Mysnychenko
Marina Yu. Penkova
Olga M. Lytvynova
Alexander E. Berezin
Vadym S. Lytvynov
Circulating microRNA-133a in Patients With Arterial Hypertension, Hypertensive Heart Disease, and Left Ventricular Diastolic Dysfunction
Frontiers in Cardiovascular Medicine
arterial hypertension
hypertensive heart disease
microRNA-133a
left ventricular diastolic dysfunction
epigenetics
author_facet Sergiy M. Koval
Iryna O. Snihurska
Kostiantyn O. Yushko
Olga V. Mysnychenko
Marina Yu. Penkova
Olga M. Lytvynova
Alexander E. Berezin
Vadym S. Lytvynov
author_sort Sergiy M. Koval
title Circulating microRNA-133a in Patients With Arterial Hypertension, Hypertensive Heart Disease, and Left Ventricular Diastolic Dysfunction
title_short Circulating microRNA-133a in Patients With Arterial Hypertension, Hypertensive Heart Disease, and Left Ventricular Diastolic Dysfunction
title_full Circulating microRNA-133a in Patients With Arterial Hypertension, Hypertensive Heart Disease, and Left Ventricular Diastolic Dysfunction
title_fullStr Circulating microRNA-133a in Patients With Arterial Hypertension, Hypertensive Heart Disease, and Left Ventricular Diastolic Dysfunction
title_full_unstemmed Circulating microRNA-133a in Patients With Arterial Hypertension, Hypertensive Heart Disease, and Left Ventricular Diastolic Dysfunction
title_sort circulating microrna-133a in patients with arterial hypertension, hypertensive heart disease, and left ventricular diastolic dysfunction
publisher Frontiers Media S.A.
series Frontiers in Cardiovascular Medicine
issn 2297-055X
publishDate 2020-07-01
description Aim: The aim of the work was to study the circulating microRNA-133a levels in blood plasma of patients with arterial hypertension (AH), hypertensive heart disease (HHD), and left ventricular (LV) diastolic dysfunction (DD).Materials and Methods: A total of 48 patients with grade 2–3 AH and HHD at the age of 52.23 ± 7.26 (23 patients had LV DD [main group] and 25 patients had normal LV diastolic function [comparison group]) and 21 practically healthy individuals of comparable gender and age were examined. Diagnosis of AH and HHD was carried out according to the 2018 ESC/ESH recommendations. LV DD was determined according to the 2016 ASE/EACVI recommendations. Plasma microRNA-133a level was obtained by polymerase chain reaction using the CFX96 Touch System (BioRad), ≪TaqMan microRNA Assay≫ and ≪TaqMan® Universal PCR Master Mix≫ reagent kits (Thermo Fisher Scientific, USA).Results: We have found that in patients from the main and comparison groups plasma microRNA-133a levels were significantly lower than in practically healthy individuals (0.094 [0.067, 0.147]) and (0.182 [0.102, 0.301]) vs. (0.382 [0.198,0.474]), p = 0.002 and p = 0.04, respectively. In all this among patients with AH, HHD, and LV DD, plasma microRNA-133a levels were significantly lower than in patients with AH, HHD, and normal diastolic function (p = 0.03). In the main and comparison groups there was a statistically significant negative relationship between plasma microRNA-133a level and left ventricular mass index (LVMI) (R = −0.40, p = 0.003 and R = −0.35, p = 0.04, respectively).Conclusions: The findings suggest the significant role of decreased microRNA-133a levels in blood plasma of patients with AH in the pathogenesis and development of both HHD and LV DD.
topic arterial hypertension
hypertensive heart disease
microRNA-133a
left ventricular diastolic dysfunction
epigenetics
url https://www.frontiersin.org/article/10.3389/fcvm.2020.00104/full
work_keys_str_mv AT sergiymkoval circulatingmicrorna133ainpatientswitharterialhypertensionhypertensiveheartdiseaseandleftventriculardiastolicdysfunction
AT irynaosnihurska circulatingmicrorna133ainpatientswitharterialhypertensionhypertensiveheartdiseaseandleftventriculardiastolicdysfunction
AT kostiantynoyushko circulatingmicrorna133ainpatientswitharterialhypertensionhypertensiveheartdiseaseandleftventriculardiastolicdysfunction
AT olgavmysnychenko circulatingmicrorna133ainpatientswitharterialhypertensionhypertensiveheartdiseaseandleftventriculardiastolicdysfunction
AT marinayupenkova circulatingmicrorna133ainpatientswitharterialhypertensionhypertensiveheartdiseaseandleftventriculardiastolicdysfunction
AT olgamlytvynova circulatingmicrorna133ainpatientswitharterialhypertensionhypertensiveheartdiseaseandleftventriculardiastolicdysfunction
AT alexandereberezin circulatingmicrorna133ainpatientswitharterialhypertensionhypertensiveheartdiseaseandleftventriculardiastolicdysfunction
AT vadymslytvynov circulatingmicrorna133ainpatientswitharterialhypertensionhypertensiveheartdiseaseandleftventriculardiastolicdysfunction
_version_ 1724649150725750784